Inconclusion, administration of 10% tilmicosin phosphate soluble powder is effective and safe to treat artificially infected swine withmycoplasmal pneumonia.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:In order to evaluate the in vivo therapeutic effect of oral administration of tilmicosin phosphate on mycoplasmal pneumoniain swine and its safety for the infected swine, the model of mycoplasmal pneumonia disease in swine was established by artificialinfection, and indices such as efficiency, cure rate, death rate, the score of lung lesion, and the routine blood tests, blood biochemistry,and routine urine tests of tested swine were determined.
📊
Temel Bulgular & Veri:The results showed that all of the dosage groups of 100 mg/L, 80 mg/L, 60 mg/Lof 10% tilmicosin phosphate soluble powder demonstrated distinct therapeutic effects on mycoplasmal pneumonia in pigs, significantlyreducing the scores of lung lesions in diseased pigs, and that the treatment effect of 60–80 mg/L tilmicosin phosphate soluble powderwas equivalent to that of 10% tilmicosin soluble powder.
💡
Sonuç & Katkı:Inconclusion, administration of 10% tilmicosin phosphate soluble powder is effective and safe to treat artificially infected swine withmycoplasmal pneumonia.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Abstract
In order to evaluate the in vivo therapeutic effect of oral administration of tilmicosin phosphate on mycoplasmal pneumoniain swine and its safety for the infected swine, the model of mycoplasmal pneumonia disease in swine was established by artificialinfection, and indices such as efficiency, cure rate, death rate, the score of lung lesion, and the routine blood tests, blood biochemistry,and routine urine tests of tested swine were determined. The results showed that all of the dosage groups of 100 mg/L, 80 mg/L, 60 mg/Lof 10% tilmicosin phosphate soluble powder demonstrated distinct therapeutic effects on mycoplasmal pneumonia in pigs, significantlyreducing the scores of lung lesions in diseased pigs, and that the treatment effect of 60–80 mg/L tilmicosin phosphate soluble powderwas equivalent to that of 10% tilmicosin soluble powder. Administration of 10% tilmicosin phosphate soluble powder improved theweight gain of the diseased swine. Treatment of infected pigs with 60–100 mg/L of 10% tilmicosin phosphate soluble powder didnot seem to influence the routine blood tests, biochemical index, and routine urine tests, and is therefore safe for diseased swine. Inconclusion, administration of 10% tilmicosin phosphate soluble powder is effective and safe to treat artificially infected swine withmycoplasmal pneumonia.
🔖
Bu Makaleye Atıf Yap
ZHANG, X., BAO, E., WU, N., PAN, J., TANG, S., LEI, X., SUN, Y., HARTUNG, J. (2022). Investigation of the efficiency and safety of tilmicosin phosphate in treating experimental mycoplasmal infections in pigs. Turkish Journal of Veterinary and Animal Sciences, Cilt: 42 - Sayı: 6, 571–580. https://ajindex.com/articles/614983
Holst S, Yeske P, Pieters M. Elimination of Mycoplasma hyopneumoniae from breed-to-wean farms: a review of current protocols with emphasis on herd closure and medication. J Swine Health Prod 2015; 23: 321-330
Blanchard B, Vena M, Cavalier A, Le Lannic J, Gouranton J, Kobisch M. Electron microscopic observation of the respiratory tract of SPF piglets inoculated with Mycoplasma hyopneumoniae. Vet Microbiol 1992; 30: 329-341
Sibila M, Pieters M, Molitor T, Maes D, Haesebrouck F, Segales J. Current perspectives on the diagnosis and epidemiology of Mycoplasma hyopneumoniae infection. Vet J 2009; 181: 221- 231
Garcia-Morante B, Segales J, Fraile L, Perez de Rozas A, Maiti H, Coll T, Sibila M. Assessment of Mycoplasma hyopneumoniae induced pneumonia using different lung lesion scoring systems: a comparative review. J Comp Pathol 2015; 154: 125-134
Michiels A, Piepers S, Ulens T, Van Ransbeeck N, Del Pozo Sacristan R, Sierens A,Maes D. Impact of particulate matter and ammonia on average daily weight gain, mortality and lung lesions in pigs. Prev Vet Med 2015; 121: 99-107
Dubosson C, Conzelmann C, Miserez R, Boerlin P, Frey J, Zimmermann W, Kuhnert P. Development of two real-time PCR assays for the detection of Mycoplasma hyopneumoniae in clinical samples. Vet Microbiol 2005; 102: 55-65
Strait E, Madsen M, Minion F, Christopher-Hennings J, Dammen M, Jones K, Thacker E. Real-time PCR assays to address genetic diversity among strains of Mycoplasma hyopneumoniae. J Clin Microbiol 2008; 46: 2491-2498
Maes D, Sibila M, Kuhnert P, Segales J, Haesebrouck F, Pieters M. Update on Mycoplasma hyopneumoniae infections in pigs: knowledge gaps for improved disease control. Transbound Emerg Dis 2017; 23: doi: 10.1111/tbed.12677
Zhang P, Hao H, Li J, Ahmad I, Cheng G, Chen D, Tao Y, Huang L, Wang Y, Dai M. The epidemiologic and pharmacodynamic cutoff values of tilmicosin against Haemophilus parasuis. Front Microbiol 2016; 7: 385
Kang S, Li Z, Yin Z, Jia R, Song X, Li L, Chen Z, Peng L, Qu J, Hu Z et al. The antibacterial mechanism of berberine against Actinobacillus pleuropneumoniae. Nat Prod Res 2015; 29: 2203- 2206
Frank GH, Briggs RE, Loan RW, Purdy CW, Zehr ES. Effects of tilmicosin treatment on Pasteurella haemolytica organisms in nasal secretion specimens of calves with respiratory tract disease. Am J Vet Res 2000; 61: 525-529
Naccari F, Giofrè F, Pellegrino M, Calò M, Licata P, Carli S. Effectiveness and kinetic behaviour of